Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS AFTER 1 YEAR OF TREATMENT WITH RILMENIDINE - A DOUBLE-BLIND, RANDOMIZED, CONTROLLED (VERSUS NIFEDIPINE) STUDY
Autore:
SADOWSKI Z; SZWED H; KUCHWOCIAL A; KUBASIK A; JANUSZEWICZ W; KRUPAWOJCIECHOWSKA B; POLAK G; STEJFA M; DVORAK I; BALAZOVJECH I; DUBAI G; SIMON K;
Indirizzi:
NATL INST CARDIOL,DEPT ISCHEM HEART DIS,SPARTANSKA 1 PL-02637 WARSAW POLAND MED ACAD WARSAW,DEPT INTERNAL MED & HYPERTENS WARSAW POLAND MED UNIV GDANSK,DEPT HYPERTENS & DIABETOL GDANSK POLAND HUNGARIAN INST CARDIOL,DEPT CLIN PHARMACOL BUDAPEST HUNGARY FAC HOSP ST ANNA,DEPT INTERNAL MED BRNO CZECH REPUBLIC COMENIUS UNIV,FAC MED BRATISLAVA SLOVAKIA BAJCSY ZSILINSZKY KORHAZ 4 BUDAPEST HUNGARY CTY HOSP,DEPT INTERNAL MED SZEKESFESHERVAR HUNGARY
Titolo Testata:
Journal of hypertension
, volume: 16, anno: 1998, supplemento:, 3
pagine: 55 - 62
SICI:
0263-6352(1998)16:<55:ROLHIH>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMIDAZOLINE RECEPTORS; MASS; VALIDATION; REVERSAL;
Keywords:
LEFT VENTRICULAR HYPERTROPHY; RILMENIDINE; NIFEDIPINE; REVERSAL OF LEFT VENTRICULAR HYPERTROPHY; ANTIHYPERTENSIVE EFFICACY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
Z. Sadowski et al., "REGRESSION OF LEFT-VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS AFTER 1 YEAR OF TREATMENT WITH RILMENIDINE - A DOUBLE-BLIND, RANDOMIZED, CONTROLLED (VERSUS NIFEDIPINE) STUDY", Journal of hypertension, 16, 1998, pp. 55-62

Abstract

Objective To assess the effect of 1-year treatment with rilmenidine, an oxazoline compound that exerts its antihypertensive effects throughbinding to imidazoline receptors in the brainstem, on left ventricular hypertrophy (LVH) secondary to essential, mild-to-moderate hypertension [supine diastolic blood pressure (DBP) 95-115 mmHg]. Methods We performed a double-blind, randomized, controlled (versus slow-release nifedipine) trial. Adjustment of treatment took place every month (M) between inclusion (M0) and an evaluation after 6 months (M6), then during Mg and after 1 year (M12) to achieve supine DBP values less than or equal to 90 mmHg. Patients were dropped from our study if they had DBP>95 mmHg during two consecutive visits or DBP>115 mmHg on one occasion. The daily dosage of rilmenidine was 1 mg, and could be increased to 2 mg/day. The daily dosage of slow-release nifedipine was started fromthe beginning at the maximum dosage of 40 mg/day, so that there was no true adjustment of treatment despite the allocation of patients to adifferent unit in the case of DBP> 95 mmHg. The primary criterion wasthe change in left ventricular mass index (LVMI, g/m(2)), assessed byechocardiography, between M0 and M12 for patients who completed the trial. Results After a 1-month placebo run-in period, 76 patients were selected and 73 were included (35 treated with rilmenidine and 38 treated with nifedipine). Fifteen patients withdrew from the study and twocompleted the study with a major deviation from protocol, leaving 56 patients (24 treated with rilmenidine and 32 treated with nifedipine) for a per-protocol analysis. Baseline demographic characteristics and history of arterial hypertension for the rilmenidine and nifedipine groups were similar, for included patients and for those taken into account for the per-protocol analysis. Between M0 and M12, DBP in members of the perprotocol population was adequately controlled for those in the rilmenidine group (102.7 +/- 4.6 versus 88.5 +/- 7.1 mmHg, respectively) and for those in the nifedipine group (102.7 +/- 5.1 versus 85.6+/- 7.9 mmHg, respectively). During M0, LVMI of patients in the rilmenidine group (176.9 +/- 41.3 g/m(2)) was slightly higher than that of patients in the nifedipine group (172.6 +/- 35.1 g/m(2)). During M12, LVMI was observed to have decreased both for patients in the rilmenidine group (to 154.8 +/- 40.2 g/m(2), a decrease of 22.1 +/- 23.3 g/m(2), P< 0.001) and for those in the nifedipine group (to 145.6 +/- 36.4 g/m(2), a decrease of 26.9 +/- 29.5 g/m(2), P<0.001) but the differencebetween these two groups was not significant (P=0.5). Conclusion One-year treatment with a daily dosage of 1 or 2 mg rilmenidine achieves asignificant reduction of left ventricular mass, which is not statistically different than that occurring with a daily dosage of 40 mg of slow-release nifedipine. I Hypertens 16 (suppl 3):S55-S62 (C) 1998 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 14:15:09